Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors.

Blood-borne therapeutics, which rely on diffusion and convection for delivery, often do not accumulate in effective concentrations distant from vasculature and are therefore unable to eradicate all cells within a tumor. Motile bacteria have the potential to overcome the diffusion and pressure gradients that prevent passive materials from penetrating into poorly perfused regions of tumors. Here, we test several proposed mechanisms of Salmonella typhimurium accumulation in tumors, including: (a) entrapment in the chaotic vasculature of tumors; (b) attraction to specific tumor microenvironments; and (c) preferential replication within specific microenvironments. After systemic injection of S. typhimurium into tumor-bearing mice, we used intravital microscopy and histological techniques to quantify their interaction with tumor vasculature. Immediately after injection, few S. typhimurium (<4 in 10,000) adhered to tumor vasculature; most remained passively suspended in the blood. Despite this low initial adhesion, approximately 10,000-fold more S. typhimurium accumulated in tumors than any other organ 1 week after the injection, thus demonstrating their specificity. However, within the tumors, we found that most bacteria were located in necrotic tissue as large colonies far (750 micro m) from functional vasculature. Together, these results suggest that S. typhimurium has limited ability to adhere to tumor vasculature and migrate within tumors and only survives in tissue that becomes necrotic. Although S. typhimurium is a promising delivery vehicle because of its tumor specificity, increasing its intra-tumoral motility should improve its therapeutic effectiveness.

[1]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[3]  R. Jain The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.

[4]  D. Bermudes,et al.  Live bacteria as anticancer agents and tumor-selective protein delivery vectors. , 2002, Current opinion in drug discovery & development.

[5]  R. Sutherland Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[6]  X. Luo,et al.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. , 2000, The Journal of infectious diseases.

[7]  R. Jain,et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.

[8]  M. Belcourt,et al.  Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. , 2002, Human gene therapy.

[9]  R. Wilson,et al.  Complete genome sequence of Salmonella enterica serovar Typhimurium LT2 , 2001, Nature.

[10]  R. B. Campbell,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[11]  P. Lambin,et al.  Clostridium spores for tumor-specific drug delivery. , 2002, Anti-cancer drugs.

[12]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[13]  R. Jain,et al.  Can engineered bacteria help control cancer? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Stocker,et al.  Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen. , 1996, Vaccine.

[15]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[17]  Kim Rutherford,et al.  Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18 , 2001, Nature.

[18]  P. Lambin,et al.  Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. , 2001, Anticancer research.

[19]  AJ Giaccia,et al.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis , 2002, Gene Therapy.